CD274 and non-small cell lung carcinoma: The discovery of immune checkpoint inhibitors was the next revolution in the therapy of NSCLC, with the programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway as the most utilized one.